Vital Therapies (NASDAQ: VTL) is one of 296 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Vital Therapies to similar businesses based on the strength of its analyst recommendations, dividends, risk, profitability, valuation, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of current ratings for Vital Therapies and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vital Therapies 0 1 2 0 2.67
Vital Therapies Competitors 768 3070 11275 227 2.71

Vital Therapies presently has a consensus target price of $8.00, indicating a potential upside of Infinity. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 23.34%. Given Vital Therapies’ higher probable upside, equities analysts plainly believe Vital Therapies is more favorable than its rivals.

Risk and Volatility

Vital Therapies has a beta of 5.3, suggesting that its stock price is 430% more volatile than the S&P 500. Comparatively, Vital Therapies’ rivals have a beta of 6.56, suggesting that their average stock price is 556% more volatile than the S&P 500.

Valuation & Earnings

This table compares Vital Therapies and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Vital Therapies N/A -$40.96 N/A
Vital Therapies Competitors $290.00 $35.57 -5.55

Vital Therapies’ rivals have higher revenue and earnings than Vital Therapies. Vital Therapies is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.


This table compares Vital Therapies and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vital Therapies N/A -70.76% -64.35%
Vital Therapies Competitors -5,397.16% -436.02% -41.59%

Institutional & Insider Ownership

25.6% of Vital Therapies shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 32.6% of Vital Therapies shares are held by company insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.


Vital Therapies rivals beat Vital Therapies on 8 of the 12 factors compared.

About Vital Therapies

Vital Therapies, Inc. is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant. The ELAD System is a liver support system containing immortal human liver-derived cells, or VTL C3A cells. The Company initiated a Phase III clinical trial in severe acute alcoholic hepatitis (sAAH), referred to as VTL-308. Its VTL-308 is a randomized, open-label, multicenter, controlled, pivotal study, designed to evaluate the ELAD System in subjects with sAAH. It is based on pre-specified and post-hoc analyses of its VTI-208 phase III clinical trial in alcohol-induced liver decompensation (AILD). The Company’s ELAD System consists of approximately four disposable ELAD C3A cell cartridges.

Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.